Non-adherence to medicines is common in patients with chronic disease and in those prescribed preventive medication. It can be intentional, unintentional, or both.
Non-adherence reduces the effectiveness of prescribed medicines and may lead the prescriber to escalate treatment unnecessarily and potentially dangerously.
Patient education, shared decision making, pharmacist support and motivational interviewing reduce intentional non-adherence.
Interventions to reduce unintentional non-adherence address patient factors including misunderstanding, confusion or forgetfulness, and factors beyond the patient’s control such as cost.
Patients should be asked about adherence at every consultation. A collaborative communication style is effective, using the patient’s own expressions and responding to their cues. Normalising non-adherence, and starting with open questions then following up with more specific probes, can also help.
Electronic reminders, such as text messaging, have been shown to increase medication adherence.
In developed countries approximately 50% of patients living with chronic disease do not adhere to treatment recommendations.1 A similar proportion do not take preventive medicines as prescribed.2 Some patients do not start their prescribed drugs. Of those who do, many subsequently discontinue. Non-adherence is a major reason why treatments shown to be efficacious in trials are often less effective in clinical practice.
Non-adherence can be classified as intentional or unintentional.3 Both reasons may contribute to non-adherence in an individual.
Intentional non-adherence is when a patient actively decides not to take a drug or follow treatment recommendations. It is likely to reflect the patient’s attitudes to medicines in general, and their specific beliefs and concerns about the treatment recommended and the disease being treated.4 A study of 99 adults and young people living with asthma identified several themes that predicted adherence to preventer medication. These included the perceived necessity of treatment, safety concerns, acceptance of disease chronicity, beliefs about treatment effectiveness, ease of use and satisfaction with asthma management.5 The opinions of friends and family, concerns about adverse effects, and experience of adverse effects were particularly salient. Studies of intentional non-adherence to other types of medication for a wide range of diseases have shown similar results.6 These findings illustrate the importance of patients’ own experiences and the views of significant others in informing the decision to take medicines.
Unintentional non-adherence is unplanned by the patient. Causes include misunderstanding or forgetfulness, and factors beyond the patient’s control such as an inability to access prescribed treatment. Multiple studies have shown that treatment complexity, cognitive impairment, cost and other practical difficulties (e.g. opening medicine bottles or difficulty swallowing pills) may reduce adherence.1
Non-adherence reduces the patient’s potential to benefit from treatment. It may also lead to unnecessary and potentially dangerous escalation of medicines.
Clinicians are poor at detecting non-adherence. In a study of 1169 patients being treated for hypertension, their doctors recognised non-adherence in fewer than half of those whose pharmacy records indicated significant gaps in dispensing. Prescribers often intensified treatment even when they suspected significant non-adherence.7 Patients should be asked about adherence at every consultation, and a poor response to treatment should always prompt detailed enquiry. A number of standardised questionnaires have been developed to measure adherence but they are not readily incorporated into routine clinical use and their psychometric properties are limited in that setting.8
A small number of studies have examined different styles of questioning by prescribers for detecting non-adherence.9-11 Effective strategies include a collaborative style, using the patient’s own expressions in responding to their utterances and cues, normalising non-adherence, and starting with open questions then following up with more specific probes (see Box). In one study, questions that asked directly about missed doses were almost four times more likely to elicit disclosure of non-adherence than other question types.11 Disclosure can be followed up with a more detailed enquiry and discussion of ways to promote adherence and overcome barriers.
Box - Asking about adherence to medicines during a consultation
Doctor: How are you going with taking your pills?
[Open question using the patient’s usual name for their tablets]
Patient: Yes, good
Doctor: Remembering to take them regularly?
[Gentle probe question]
Patient: Yes, usually
Doctor: Many people forget to take their pills occasionally
[Normalising statement responding to patient’s answer to the probe question]
Doctor: Just thinking about the last couple of weeks – have you missed taking your pills on any occasion?
[Specific probe asking directly about missed doses]
Addressing intentional non‑adherence
A systematic review explored patient-centred interventions to improve adherence, including patient education, shared decision making and pharmacist support.12 Many educational interventions resulted in better adherence and greater patient knowledge. However, their impact on adherence typically decreased over time. Shared decision making (including the use of decision aids) increased patient knowledge, but adherence improved in only two out of four studies.12 Adherence also improved with interventions by pharmacy staff, when they were tailored to patient needs, often involving both face-to-face and telephone encounters.
Motivational interviewing is a patient-centred counselling technique that aims to encourage behaviour change by reinforcing positive intentions and challenging negative ideas. It has been shown to improve adherence in a variety of settings.13,14 However, not all studies show benefit and the time pressures of routine clinical practice can limit applicability.15
Reducing unintentional non‑adherence
Interventions that address unintentional non-adherence seek to reduce barriers and improve the patient’s ability to take medicines as prescribed. A wide range of strategies has been studied.
Out-of-pocket cost is a well-recognised barrier to accessing medicines.16 In a recent survey, the Australian Bureau of Statistics reported that 7.6% of patients who had received a prescription delayed getting the medicine, or did not get it at all, due to cost. The proportion was even higher in areas of disadvantage.17 Prescribers may be able to reduce the impact of cost by, for example, prescribing generic or lower cost medicines when appropriate. Pharmacists may also assist patients by recommending lower cost brands.
Patients can be confused by the number and variety of medicines they need to take. Adherence has long been known to be inversely associated with the complexity of the regimen.18 Prescribers should aim to simplify this as much as possible. Discussion with a pharmacist may assist, particularly with tailoring appropriate preparations, formulations and packaging for the individual (e.g. people with an inability to swallow).19 These consultations may be rebatable in Australia using the Medicare medication management review items. It may be possible to reduce the frequency of administration, introduce combination medicines, or even deprescribe in some instances.20
It is good practice to provide patients with a printed list of their medicines and the times of day when they should be administered. Alternatively, the patient may be encouraged to use a smartphone app such as the NPS MedicineWise MedicineList+. The patient’s understanding of their regimen should be checked. For patients with cognitive impairment, the support of a carer to encourage or assist with administration is essential.
Brand swapping when medicines are dispensed may cause confusion and impair adherence. Pharmacists have a responsibility to educate patients if they swap brands, and prescribers should explain to patients and carers when they may be offered a choice.
Fixed-dose combinations can be helpful for patients on multiple medicines, and have been shown to improve adherence in some circumstances.21 Starting treatment with combination medicines has a strong evidence base in the management of HIV and other infections. For conditions such as hypertension, the evidence for starting with more than one medicine is mixed, but the strategy should be considered.22
Reminder packaging, which incorporates a date or time for a medicine to be taken, is an effective way of promoting adherence and has been shown to improve biological outcomes in type 2 diabetes and hypertension.23 Drug administration aids are a form of reminder packaging and may be particularly helpful for patients prescribed multiple medicines. However, they are not suitable in all circumstances.24 The stability of some drugs may be compromised by repackaging.25 Patients with impaired cognition, eyesight or dexterity often have difficulty using them. Repackaging by the pharmacist may increase the cost to the patient and filling a compartmentalised box at home can lead to errors. Also, such boxes are rarely childproof.26
There is strong evidence that regular reminders are an effective strategy for increasing adherence.27 Electronic devices can assist with this. In a randomised controlled trial, 143 adults with asthma used combination fluticasone propionate/salmeterol inhalers with attached electronic monitoring devices. The device recorded inhaler activation and provided twice-daily reminders for missed doses to those in the intervention group. Over six months, adherence was over 50% higher in the intervention group than in the control group.28
A meta-analysis evaluating the use of text messaging in adults with chronic disease found it doubled the odds of adherence across 16 randomised controlled trials. The effect was not dependent on message characteristics such as personalisation, two-way communication or daily frequency.29
As new information and communication technologies develop, new strategies for promoting and monitoring adherence are emerging. An example is ‘smart pills’ which send a signal to an external monitor when a tablet has been ingested. The signal can be linked to automated adherence reminders and to a medication reconciliation system.30
Medicines do not work if they are not administered. Non-adherence, whether by intent or due to cost, complexity, or forgetfulness, is a major cause of reduced effectiveness and hence of preventable morbidity and mortality. Evidence-based strategies are available to address both intentional and unintentional non-adherence.
Tim Usherwood is a member of the Editorial Executive Committee of Australian Prescriber.
- Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003.
- Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125:882-7.e1.
- Hugtenburg JG, Timmers L, Elders PJM, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence 2013;7:675–82.
- Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
- Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, Rand CS, et al. Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. Intern Med J 2012;42:e136-44.
- Laba TL, Essue B, Kimman M, Jan S. Understanding patient preferences in medication nonadherence: a review of stated preference data. Patient 2015;8:385-95.
- Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res 2012;12:270.
- Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015;2015:217047.
- Steele DJ, Jackson TC, Gutmann MC. Have you been taking your pills? The adherence-monitoring sequence in the medical interview. J Fam Pract 1990;30:294-9.
- Bokhour BG, Berlowitz DR, Long JA, Kressin NR. How do providers assess antihypertensive medication adherence in medical encounters? J Gen Intern Med 2006;21:577-83.
- Callon W, Saha S, Korthuis PT, Wilson IB, Moore RD, Cohn J, et al. Which clinician questions elicit accurate disclosure of antiretroviral non-adherence when talking to patients? AIDS Behavior 2016;20:1108-15.
- Kuntz JL, Safford MM, Singh JA, Phansalkar S, Slight SP, Her QL, et al. Patient-centered interventions to improve medication management and adherence: a qualitative review of research findings. Patient Educ Couns 2014;97:310-26.
- VanBuskirk KA, Wetherell JL. Motivational interviewing used in primary care. A systematic review and meta-analysis. J Behav Med 2014;37:768–80.
- Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care 2012;24:583-92.
- Foster JM, Smith L, Usherwood T, Sawyer SM, Reddel HK. General practitioner-delivered adherence counseling in asthma: feasibility and usefulness of skills, training and support tools. J Asthma 2016;53:311-20.
- Sinnott SJ, Buckley C, O’Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One 2013;8:e64914.
- Australian Bureau of Statistics. 4839.0 - Patient experiences in Australia: summary of findings, 2015-16. 15 November 2016. [cited 2017 Jul 1]
- Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-42.
- Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open 2015;5:e009235.
- Le Couteur D, Gnjidic D, McLachlan A. Deprescribing. Aust Prescr 2011;34:182-5.
- Webster R, Patel A, Selak V, Billot L, Bots M, Brown A, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. Intern J Cardiol 2016;205:147-56.
- National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults - 2016. Melbourne: National Heart Foundation of Australia; 2016. [cited 2017 Jul 1]
- Mahtani KR, Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev 2011:CD005025.
- Elliott RA. Appropriate use of dose administration aids. Aust Presc 2014;37:46-50.
- Haaywood A, Llewelyn V, Robertson S, Mylrea M, Glass B. Dose administration aids: pharmacists’ role in improving patient care. Australas Med J 2011;4:183–9.
- Barker R. When is child-resistant packaging not child resistant? Aust Prescr 2013;36:194.
- Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010:CD004371.
- Foster JM, Usherwood T, Smith L, Sawyer SM, Xuan W, Rand CS, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin Immunol 2014;134:1260-8.e3.
- Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med 2016;176:340-349.
- Granger BB, Bosworth H. Medication adherence: emerging use of technology. Curr Opin Cardiol 2011;26:279–87.